SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " mace " 315 found 🔀 AI-powered Shuffle
The Weight-Loss Drug Revolution—From Shots to Pills and the Science behind It All
Behind the hype of GLP-1 medications lies complex science, serious side effects and a pharmaceutical arms race.
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
Trump announces deals with nine drug companies, aiming to lower cost of medicine
In his latest effort to lower drug costs, President Donald Trump unveiled Friday “Most Favored Nation” pricing deals with nine more pharmaceutical companies.
Trump secures agreements with major drugmakers to lower Medicaid prescription costs for Americans
President Donald Trump announced Friday that nine additional pharmaceutical companies joined its most-favored-nation pricing initiative.
Vertex Forward: Our animated video series
Watch the animated video series “Vertex Forward” to see the Vertex Pharmaceuticals philosophy and strategy explained.
Insmed Provides Clinical and Business Update
/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Provides Clinical and Business Update
Insmed Incorporated (Nasdaq:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, announced today that the Phase 2b BiRCh study of brensocatib in patients with chronic rhinosinusitis without nasal polyps (CRSsNP) did not meet its primary or secondary efficacy endpoints in either the 10 mg or 40 mg treatment arms. Brensocatib was well tolerated, with no new safety signals identified
How NIH-Funded Science Supports US Biopharmaceutical Innovation
NIH-funded research supports the foundation for industry to develop vaccines and therapies, exemplifying deep public-private R&D complementarity. As global competition intensifies, expanding NIH funding will be key to protecting American health, supporting U.S. biopharmaceutical competitiveness, and ensuring national power and security.
‘I blame our party’: Nancy Mace calls out Republicans for being ineffective
Nancy Mace escalated airport incident into ‘spectacle’, police investigation says
Republican congresswoman berated TSA personnel in October with profanity and insults, leaving facility employees ‘visibly upset’
Police investigation faults Nancy Mace for profanity-laced airport tirade
A report found Rep. Nancy Mace (R-South Carolina) turned a “minor miscommunication” by police into a “spectacle” during a recent encounter at Charleston International Airport.
SPONSORED Novartis makes $23 billion investment in America's health
Ten facilities – including seven new sites – will create thousands of jobs and accelerate U.S. pharmaceutical innovation.
Holland & Knight Health Dose: December 3, 2025 | Insights
The Trump Administration finalized a trade agreement with the UK that exempts British-origin pharmaceuticals, ingredients and medical technology from Section 232 tariffs.
Opterion Health AG Announces Appointment of Andreas Schuh as Chief Financial Officer
MUTTENZ, Switzerland, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a clinical-stage biopharmaceutical company pioneering innovation in peritoneal dialysis (PD), is pleased to announce the appointment of Andreas Schuh as Chief Financial Officer (CFO), effective December 1, 2025. Andreas Schuh joins Opterion with over 20 years of leadership experience across biotech, pharma, and medical devices. He has held senior finance and operations roles at Nuclidium, Jeito, Roivant, Novartis, and Al